期刊文献+

多发性硬化伴发抑郁症患者血清细胞因子变化研究 被引量:2

Research of cytokines change in multiple sclerosis patients with depression
下载PDF
导出
摘要 目的探讨多发性硬化(MS)伴发抑郁症患者血清细胞因子白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)的变化。方法选取MS伴发抑郁症患者30例,采用酶联免疫吸附试验(ELISA)检测其血清细胞因子IL-1β、IL-6和TNF-α水平,并选择MS不伴抑郁症患者作为对照组进行比较。抑郁症组患者每日给予抗抑郁药物盐酸舍曲林20mg,连续用药4周,观察其疗效及上述细胞因子水平变化。结果 MS伴发抑郁症患者血清IL-1β、IL-6和TNF-α水平均高于MS不伴抑郁症对照组,差异有统计学意义(P<0.01);MS伴抑郁症患者应用盐酸舍曲林抗抑郁治疗总有效率为73.3%,治疗后血清IL-1β、IL-6和TNF-α水平均较治疗前下降,差异有统计学意义(P<0.05)。结论 IL-1β、IL-6和TNF-α与MS伴发抑郁症存在相关性,提示MS可能通过细胞因子的作用激活了抑郁症的发生。 Objective To investigate the change of interleukin (IL)-1beta (IL-1β),IL-6 and interferon(IFN)-alpha(TNF-α)in multiple sclerosis(MS) with depression.Methods Thirty patients of MS with depression and thirty patients of MS without depression as control were involved in the study.These patients were detected the concentration of IL-1β,IL-6,TNF-α.And the depression patients were detected the concentration of IL-1β,IL-6,TNF-α again after administrating with sertraline four weeks.Results The concentration of IL-1β,IL-6 and TNF-α in the MS patients with depression were higher than that in the MS patients without depression.73.3% of the MS patients with depression were treated effectively.The concentration of IL-1β,IL-6 and TNF-α in the MS patients with depression was reduced after antidepressant treatment.Conclusion The MS patients with depression have correlation with cytokines of IL-1β,IL-6 and TNF-α.The results may suggest that the role of cytokines may activate the occurrence of depression in MS.
出处 《检验医学与临床》 CAS 2010年第13期1290-1291,共2页 Laboratory Medicine and Clinic
关键词 多发性硬化 抑郁症 白细胞介素类 肿瘤坏死因子Α 酶联免疫吸附测定 multiple sclerosis depressive disorder interleukins tumor necrosis factor-alpha enzyme-linked immunosorbent assay
  • 相关文献

参考文献8

  • 1Dalton EJ, Heinrichs RW. Depression in multiple sclerosis: a quantitative review of the evidence[J]. Neuropsy chology, 2005,19 : 152-158.
  • 2Reiss JP,Sam D, Sareen J. Psychosis in multiple sclerosis associated with left temporal lobe lesions on serial MRI scans[J]. J Clin Neurosci, 2006,13: 282-284.
  • 3谢琰臣,张华,许贤豪,胡夏生,吕继辉,刘银红,乔立艳,孟晓梅,冯凯.多发性硬化患者抑郁的研究[J].中国神经免疫学和神经病学杂志,2005,12(2):100-102. 被引量:14
  • 4Dunn AJ,Swiergiel AH, Beaurepaire R. Cytokines as mediators of depression: what can we learn from animal studies[J]. Neurosci Biobehav Rev, 2005,29 (4-5) : 891- 909.
  • 5Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protoeols[J]. Ann Neurol, 1983,13 : 227-231.
  • 6Ozenei V, Kouwenhoven M, Link H. Cytoklnes in multiple sclerosis: methodological aspects and pathogenic implications[J]. Mult Scler,2002,8:396-404.
  • 7Irwin MR, Miller AH. Depressive disorders and immunity:20 years of progress and disvovery[J]. Br Behav Immun, 2007,21 : 374-378.
  • 8Maes M. The cytokine hypothesis of depression: inflammation,oxidative and nitrosative stress and leaky gut as new targets for adjunctive treatments in depression[J]. Neurol Endocrinol Lett, 2008,29 : 287-291.

二级参考文献7

  • 1Nyenhuis DL, Rao SM, Zajecka JM, et al. Mood disturbance versus other symptoms of depression in multiple sclerosis[J]. J Int Neuropsychol Soc, 1995, 1:291-296.
  • 2Aikens JE, Fischer JS, Namey M, et al. A replicated prospective investigation of life stress, coping, and depressive symptoms in multiple sclerosis[J]. J Behav Med, 1997, 20:433-445.
  • 3中华医学会精神科分会.中国精神障碍分类与诊断标准[M],第3版(CCMD-3)[M].济南:山东科学技术出版社,2001.83-114.
  • 4Walther EU, Hohlfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management[J]. Neurology, 1999, 53:1622-1627.
  • 5European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis[J]. Lancet, 1998, 352: 1491-1497.
  • 6Feinstein A, Roy P, Lobaugh N, et al. Structural brain abnormalities in multiple sclerosis patients with major depression[J]. Neurology, 2004, 62: 586-590.
  • 7Patten SB, Beck CA, Williams JV, et al. Major depression in multiple sclerosis: a population-based perspective[J]. Neurology, 2003, 61:1524-1527.

共引文献13

同被引文献12

  • 1谢琰臣,张华,许贤豪,胡夏生,吕继辉,刘银红,乔立艳,孟晓梅,冯凯.多发性硬化患者抑郁的研究[J].中国神经免疫学和神经病学杂志,2005,12(2):100-102. 被引量:14
  • 2Mcdonald WI, Compston A, Edan G, et al. Recommended diagnosticcriteria for multiple sclerosis: guidelines from the International Panel onthe diagnosis of multiple sclerosis [ J] . Ann Neurol, 2001, 50 ( 1 ):121 -132.
  • 3Dalton E J, heinrichs RW. Depression in multiple sclerosis:a quantita- tive review of the evidence [ J ]. Neuropsychology, 2005, 19 ( 2 ) : 152-158.
  • 4Boeru G, Milanov I, De Robertis F, et al. ExtaviJect 30G device for sub- cutaneous self-injection of interferon beta-1 b for multiple sclerosis: a prospective European study [ J ]. Med Devices ( Auckl ) , 2015, 6 : 175-184.
  • 5Feinstein A. Neuropsychiatric syndromes associated with multiple scle- rosis[J]. J Neurol,2008,255(2) :309-310.
  • 6Beiske AG, Svensson E, Sandanger I, et al. Appropriate treatment for patients suffering from MS Depression and anxiety amongst multiple sclerosis patients[ J l. Eur J Neurol,2008,15 ( 3 ) :239-245.
  • 7BrCnnum-Hansen H,Stenager E, Nylev Stenager E, et al. Suicide among Danes with multiple sclerosis[ J]. J Neurol Neurosurg Psychiatry,2005, 76(10) :1457-1459.
  • 8Zorzon M, Zivadinov R, Nasuelli D, et al. Depressive symptoms mad MRI changes in multiple sclerosis [ J ]. Eur J Neurol,2002,9 (5) :491-496.
  • 9Dunn AJ, Swiergie[ AH, Beaurepaire R. Cytokines as mediators of de- pression:what can we learn from animal sludiesE J ]. Neurosci Biobehav Rev,2005,29(4-5) :891-909.
  • 10丁立东,刘颖,茆华武.多发性硬化复发68例临床分析[J].实用临床医药杂志,2010,14(5):112-113. 被引量:3

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部